GSK-7975A   Click here for help

GtoPdb Ligand ID: 10088

Synonyms: example 36 [US20120053150A1] | GSK7975A
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GSK-7975A was designed as a calcium-release activated calcium (CRAC) channel inhibitor [2]. The structure is claimed as Example 36 in Glaxo patent US20120053150A1 [1]. GSK-7975A inhibits (blocks) the Orai1 component of the CRAC channel complex [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 67.15
Molecular weight 397.08
XLogP 4.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Oc1ccc(c(c1)C(F)(F)F)Cn1ccc(n1)NC(=O)c1c(F)cccc1F
Isomeric SMILES Oc1ccc(c(c1)C(F)(F)F)Cn1ccc(n1)NC(=O)c1c(F)cccc1F
InChI InChI=1S/C18H12F5N3O2/c19-13-2-1-3-14(20)16(13)17(28)24-15-6-7-26(25-15)9-10-4-5-11(27)8-12(10)18(21,22)23/h1-8,27H,9H2,(H,24,25,28)
InChI Key CPYTVBALBFSXSH-UHFFFAOYSA-N
Bioactivity Comments
GSK-7975A completely inhibits calcium influx through CRAC channels in vitro [2]. GSK-7975A was used to show that CRAC channel activity is essential for mast cell and T cell function. The rat channel displays a similar pharmacology to human CRAC channels, so this compound is suitable for in vivo rat studies with translational potential to human.
Selectivity at ion channels
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Orai1 Hs Channel blocker Inhibition 6.4 pIC50 - 3
⤷ pIC50 6.4 (IC50 3.98x10-7 M) [3]
Description: In vitro inhibition of calcium entry mediated by Orai1/STIM1 CRAC channels.
Orai2 Hs Channel blocker Inhibition 5.8 pIC50 - 3
⤷ pIC50 5.8 (IC50 1.453x10-6 M) [3]
Description: In vitro inhibition of calcium entry mediated by Orai2/STIM1 CRAC channels.